1403332-61-5

Basic information

• Product Name: (S)-N-(1-(3-(3-Chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-3-isopropyl-1,2,4-oxadiazole-5-carboxamide
• Synonyms: (S)-N-(1-(3-(3-Chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-3-isopropyl-1,2,4-oxadiazole-5-carboxamide
• CAS NO: 1403332-61-5
• Molecular Weight: 416.842
• Mol File: 1403332-61-5.mol

Chemical Properties

• CAS DataBase Reference: (S)-N-(1-(3-(3-Chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-3-isopropyl-1,2,4-oxadiazole-5-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-(1-(3-(3-Chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-3-isopropyl-1,2,4-oxadiazole-5-carboxamide(1403332-61-5)
• EPA Substance Registry System: (S)-N-(1-(3-(3-Chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-3-isopropyl-1,2,4-oxadiazole-5-carboxamide(1403332-61-5)

Safety Data

• Hazardous Substances Data: 1403332-61-5(Hazardous Substances Data)

Upstream product

• 1297540-76-1 2-chloro-6-fluoro-4-(1H-pyrazol-3-yl)benzonitrile 
• 1297540-77-2 (S)-4-(1-(2-aminopropyl)-1H-pyrazol-3-yl)-2-chloro-6-fluorobenzonitrile 
• 944906-38-1 3-Isopropyl-1,2,4-oxadiazole-5-carboxylic acid 
• 1297540-76-1 2-Chloro-6-fluoro-4-(1H-pyrazol-5-yl)benzonitrile 
• 163719-70-8 Ethyl 3-isopropyl-1,2,4-oxadiazole-5-carboxylate 

Relevant articles and documents

ANDROGEN RECEPTOR MODULATING CARBOXAMIDES

Compounds of formula (I) or (II) wherein Rx, Rz, R9, R10, R14, R14′, R15, R15′, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

ANDROGEN RECEPTOR MODULATING CARBOXAMIDES

Compounds of formula (I) wherein Rx, Rz, R9, R10, R14, R14', R15, R15', A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.